For the third quarter of 2026, analysts anticipate Humana Inc will report consensus revenue of $40.87 billion and an adjusted loss per share of $1.03, with the stock currently trading near $414.50 against a $430.85 average price target.
Investors are primarily focused on the Medical Benefit Ratio (MBR) as the definitive measure of medical cost management within the core Medicare Advantage segment for the Q3 2026 period.
Sentiment improved significantly following stronger-than-expected 2027 Star Ratings, which positioned 95% of members in 4.0-star plans or higher for the upcoming cycle. However, management must still prove it can control the elevated utilization and reimbursement headwinds that have pressured 2026 margins, making this report critical for confirming operational stability.